AdvisorShares Trust holds 6.78% stake in Psyence Biomedical

AdvisorShares Trust reports significant stake in Psyence Biomedical

AdvisorShares Trust has disclosed a 6.78% ownership stake in Psyence Biomedical Ltd., according to a Schedule 13G filing with the U.S. Securities and Exchange Commission (SEC) dated October 5, 2026. This filing reveals that the investment firm holds 258,538 common shares of the company as of September 30, 2026.

Details of the SEC filing

The Schedule 13G filing indicates that AdvisorShares Trust possesses sole voting and dispositive power over the shares, meaning it has the authority to vote and make decisions regarding the sale of these shares. The firm does not share this power with any other entity, according to the document.

Regulatory context

The filing was made under Rule 13d-1(b) of the Securities Exchange Act, which requires entities holding more than 5% of a company's shares to disclose their holdings. AdvisorShares Trust is registered in Delaware and operates as an investment company under the Investment Company Act of 1940.

Why it matters

The disclosure of a significant stake by AdvisorShares Trust in Psyence Biomedical is noteworthy as it reflects the investment firm's confidence in the company's potential. Psyence Biomedical is involved in the development of treatments using psychoactive compounds, including ibogaine, which is being explored for its therapeutic benefits in various mental health and neurological conditions.

Understanding who holds significant shares in a company can provide insights into potential future corporate actions and the strategic direction of the company. Such disclosures are crucial for investors and stakeholders who monitor changes in ownership that could influence company policies or market performance.

Psyence Biomedical is headquartered in Toronto, Ontario, and is engaged in advancing research in the field of psychedelic medicine.